90764-89-9

Usage

Uses

Used in Pharmaceutical Development:
4-AMINO-6-METHYL (1H)INDAZOLE is used as a key building block for the synthesis of various pharmaceutical compounds due to its unique structural features and potential biological activities. Its presence in drug molecules can contribute to desired therapeutic effects, such as anti-inflammatory and anti-cancer properties, which are crucial for the treatment of various diseases and conditions.
Used in Organic Synthesis:
In the field of organic synthesis, 4-AMINO-6-METHYL (1H)INDAZOLE serves as a valuable intermediate for the creation of complex organic molecules. Its reactivity and functional groups allow for a wide range of chemical reactions, facilitating the development of new compounds with specific applications in various industries.
Used in Drug Discovery:
4-AMINO-6-METHYL (1H)INDAZOLE is utilized as a starting point in drug discovery processes, where its potential biological activities are explored and optimized for therapeutic use. Researchers investigate its interactions with biological targets to develop new drugs with improved efficacy and safety profiles.
Used in Research and Development:
In academic and industrial research settings, 4-AMINO-6-METHYL (1H)INDAZOLE is employed as a subject of study to understand its properties and potential applications. This includes investigating its mechanism of action, stability, and how it can be modified or combined with other compounds to create novel therapeutic agents.

Upstream product

• 857773-68-3 6-methyl-4-nitro-1(2)H-indazole 
• 106-42-3 para-xylene 
• 609-92-7 2,5-dimethyl-1,3-dinitrobenzene 
• 62564-50-5 2,5-dimethyl-3-nitroaniline 

Downstream Products

• 1160376-44-2 phenylmethyl 3-{6-methyl-4-[((2S)-2-{[(2,4,6-trimethylphenyl)sulfonyl]amino}propyl)amino]-1H-indazol-1-yl}benzoate 
• 1160376-53-3 phenylmethyl 4-{6-methyl-4-[((2S)-2-{[(2,4,6-trimethylphenyl)sulfonyl]amino}propyl)amino]-1H-indazol-1-yl}benzoate 
• 1160376-72-6 N-((1S)-2-{[1-(3-{[3-(hydroxymethyl)-1-piperidinyl]carbonyl}phenyl)-6-methyl-1H-indazol-4-yl]amino}-1-methylethyl)-2,4,6-trimethylbenzenesulfonamide 
• 1274686-94-0 C₃₀H₃₆N₆O₄S 
• 1160376-89-5 N-[(1R)-2-amino-1-methyl-2-oxoethyl]-3-{6-methyl-4-[((2S)-2-{[(2,4,6-trimethylphenyl)sulfonyl]amino}propyl)amino]-1H-indazol-1-yl}benzamide 
• 1160376-92-0 N-(2-amino-2-oxoethyl)-3-{6-methyl-4-[((2S)-2-{[(2,4,6-trimethylphenyl)sulfonyl]amino}propyl)amino]-1H-indazol-1-yl}benzamide 
• 1160376-93-1 N-cyclopropyl-3-{6-methyl-4-[((2S)-2-{[(2,4,6-trimethylphenyl)sulfonyl]amino}propyl)amino]-1H-indazol-1-yl}benzamide 
• 1274686-90-6 C₃₀H₃₇N₅O₃S 
• 1160376-69-1 N-[(1S)-2-amino-1-methyl-2-oxoethyl]-4-(6-methyl-4-{[(2S)-2-{[(2,4,6-trimethylphenyl)sulfonyl]amino}propyl]amino}-1H-indazol-1-yl)benzamide 
• 1160376-82-8 N-[(1R)-2-amino-1-methyl-2-oxoethyl]-4-{6-methyl-4-[((2S)-2-{[(2,4,6-trimethylphenyl)sulfonyl]amino}propyl)amino]-1H-indazol-1-yl}benzamide 
• 1160376-80-6 N-(2-amino-2-oxoethyl)-4-{6-methyl-4-[((2S)-2-{[(2,4,6-trimethylphenyl)sulfonyl]amino}propyl)amino]-1H-indazol-1-yl}benzamide 
• 1274687-28-3 C₁₅H₁₅N₃O₂S 
• 1274687-26-1 C₁₅H₁₂N₄ 
• 1274687-23-8 C₁₄H₁₂FN₃ 

Relevant academic research and scientific papers

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Indazole compounds containing nitrogen substituents, and application of same as IDO inhibitors

The invention discloses nitrogen substituent-containing indazole compounds as shown in a formula (I) which is described in the specification, a preparation method for the compounds, and application ofthe compounds as IDO inhibitors. The compounds provided by the invention can be used for preventing and/or treating a plurality of diseases, such as Alzheimer's disease, cataract, infections relatedto cellular immune activation, autoimmune diseases, AIDS, cancers, depression, the metabolic disorder of tryptophan or the like.

Method for preparing 1H-indazole derivative

The invention discloses a method for preparing a 1H-indazole derivative. The method takes a compound as a formula (A1) or a compound as a formula (A2) as raw materials, and the compound as the formula(A1) and the compound as the formula (A2) are subjected